An analysis based on the phase 3 TRANSFORM and TRANSCEND trials shows an increase in cost-effectiveness, life-years, and quality-adjusted life-years compared with standard of care in patients with relapsed/refractory diffuse large B-cell lymphoma.

View Article

Early discontinuation of a hypomethylating agent was associated with an increase in economic burden for those with refractory anemia with excess blasts, a diagnosis that overlaps with high-risk myelodysplastic syndrome.

View Article

Investigators have identified an association between the diagnosis and care of older patients with multiple myeloma and substantial financial burden on Medicare.

View Article

A real-world study found patients with relapsed/refractory multiple myeloma who were triple-class exposed had higher healthcare costs and unmet treatment needs.

View Article

Survival among patients with multiple myeloma appears to be influenced by factors such as socioeconomic status and treatment facility type.

View Article

A synthesis of P-values across 16 studies in different global regions found that socioeconomic status continues to be a significant prognostic factor of overall survival for patients with multiple myeloma.

View Article